PILA PHARMA

Vägbeskrivning Webbplats Kontakta affären

PILA PHARMA We pioneer a new oral treatment for , and , based on inhibition 💊 We are developing a new diabetes drug

: PILA PHARMA has dosed the first subjects in the safety part of PP-CT04, a clinical trial investigating the company’s ...
13/10/2026

: PILA PHARMA has dosed the first subjects in the safety part of PP-CT04, a clinical trial investigating the company’s oral antagonist in people living with 💊

Link to the press release in the comments!

Photo: Founder and CSO Dorte X. Gram

: FIRST CLINICAL SITE INITIATED AND ACTIVATED, ENROLLMENT COMMENCES FOR SAFETY PART 1 OF PP-CT04, A 12-WEEK CLINICAL TR...
29/09/2026

: FIRST CLINICAL SITE INITIATED AND ACTIVATED, ENROLLMENT COMMENCES FOR SAFETY PART 1 OF PP-CT04, A 12-WEEK CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY

PILA PHARMA is delighted to share that following site initiation visit, the site has been activated and is enabled to start enrollment of patients for PP-CT04, our next clinical trial in people living with ! 🌟

As a reminder: PP-CT04 is a two-part, randomised, double-blind, placebo-controlled, parallel-group, 12‑week trial investigating the safety, tolerability, pharmacokinetics and efficacy of PILA PHARMA's investigational candidate, the oral small molecule antagonist XEN-D0501, in obese participants 🎯

The trial is designed to explore a within-subject dose titration approach to reach anticipated therapeutic plasma concentrations of XEN-D0501 not previously investigated 📊

PILA PHARMA Founder and CSO Dorte X. Gram comments:

"The initiation and activation of the clinical site are important milestones as it concludes weeks of formal preparation following the regulatory approval of the trial, whereby numerous documents for compliant trial ex*****on are completed. The site initiation visit itself allows for the Sponsor, PILA, to meet the actual trial staff, share our story, and our vision for developing a TRPV1 antagonist as treatment of obesity and co-morbidities, a simple, accessible tablet solution with a differentiated safety profile, that could be a good fit to current market needs." 🌍

For more information, please find the press release in the comments!

🏃‍➡️ Taking the next steps toward mid-late stage clinical trials! PILA PHARMA recently received regulatory approval to i...
16/09/2026

🏃‍➡️ Taking the next steps toward mid-late stage clinical trials!

PILA PHARMA recently received regulatory approval to initiate the PP-CT04 study – an important step in the development of the company’s antagonist for and other indications.

The new study involves significantly higher doses and a longer treatment duration than its predecessor, PP-CT02, putting tolerability in focus, an area where TRPV1 antagonists as a drug class have historically faced challenges.

BioStock - Connecting Innovation & Capital spoke with CEO Gustav H. Gram about the study’s design, where the company will be closely monitoring during the dose escalation phase, and how the results could impact further development – not only within obesity, but also for other potential indications such as and .

Link to the full interview in the comments!

💡 New report from Analyst Group! Last week, following the significant news of regulatory approval for our upcoming PP-...
16/09/2026

💡 New report from Analyst Group!

Last week, following the significant news of regulatory approval for our upcoming PP-CT04 trial in people with , and our H1 report, the analyst Axel Ljunghammer published a new research report on PILA PHARMA and comments:

"As the industry seeks alternative mechanisms for improved weight loss and a more balanced tolerability profile, XEN-D0501 is assessed to be well positioned, as the candidate does not affect gut hormones and may thereby enable a higher quality weight loss. The candidate is assessed to be scalable, expected to be decisive in making obesity drugs more accessible. (...) Analyst Group views the approval as the gate that needed to be passed for value development to be driven by clinical results. We consider that the potential in relation to the risks is not reflected in the current valuation, where an rNPV model derives SEK 5.5 (5.7) per share in a Base scenario." 🌟

The whole research report can be found in the comments 📖

14/09/2026

🔔 “The preparations for the start of the upcoming study PP-CT04 is ongoing, so during the rest of 2026, we expect there will be a good flow of news”
- CEO Gustav H. Gram


💡 Catch up on the recent news with our last report and the regulatory approval for a new longer clinical trial in people with with our oral antagonist, a potential first-in-class candidate!



If you missed the interview with Direkt Studios with a recap of the H1 report, look no further. It is available at the link in comments.

14/09/2026

🔥 "For , we would absolutely love to do more, and from a mechanistic standpoint, using a antagonist should work to alleviate the pain these patients experience. Right now we await the outcome of PP-CT04 to have a much better potential starting point"

- CEO Gustav H. Gram

💡 Catch up on the recent news with our last report and the regulatory approval for a new longer clinical trial in people with with our oral antagonist, a potential first-in-class candidate!



If you missed the interview with Direkt Studios with a recap of the H1 report, look no further. It is available at the link in comments.

14/09/2026

🤝 “We're delighted we got the regulatory for this longer trial in people with , so we'll now be approaching our contacts at various pharma companies to update them on the recent developments”

- CEO Gustav H. Gram

💡 Catch up on the recent news with our last report and the regulatory approval for a new longer clinical trial in people with with our oral antagonist, a potential first-in-class candidate!



If you missed the interview with Direkt Studios with a recap of the H1 report, look no further. It is available at the link in comments.

08/09/2026

🎯 “The ambition and goal of PP-CT04 is to have much better knowledge of what the potential best starting point is for patients, to ensure that we could potentially achieve effects”
- CEO Gustav H. Gram

💡 Catch up on the recent news with our last report and the regulatory approval for a new longer clinical trial in people with with our oral antagonist, a potential first-in-class candidate!

If you missed the interview with Direkt Studios with a recap of the H1 report, look no further. It is available at the link in comments.

08/09/2026

💊 “Analysts are starting to realise and vocalise now that oral solutions will take a larger part of the market - purely because it’s also becoming a very consumer based area of business. Oral 's however carry the known GI problems (…) so having alternative and oral solutions is definitely in favour for any company wishing to play a role in this area.”

- CEO Gustav H. Gram

💡 Catch up on the recent news with our last report and the regulatory approval for a new longer clinical trial in people with with our oral antagonist, a potential first-in-class candidate!



If you missed the interview with Direkt Studios with a recap of the H1 report, look no further. It is available at the link in comments.

The reaction on Helge Larsen says it all! 😱😉 Our CSO Dorte X. Gram has been back for another chat with him and after t...
08/09/2026

The reaction on Helge Larsen says it all! 😱😉

Our CSO Dorte X. Gram has been back for another chat with him and after the significant milestone of getting regulatory approval for our next 3-month study in people with with our oral small-molecule antagonist! 🌟

As always it turns into a nerdy talk on Dorte's background at and the learnings of and the early years of development on incretins, and the driving factor for pursuing her own discovery, that may play a role in ! 🤓

The interview is ready now (in Danish) at the youtube link in the comments, and will also be uploaded with english subtitles to PILA PHARMA's channel soon!

Adress

Norra Vallgatan 72, 5 Place
Malmö
21122

Webbplats

Aviseringar

Bli först med att veta: vi skickar ett mejl när PILA PHARMA publicerar nyheter och kampanjer. Din e-postadress används inte till något annat, och du kan avsluta prenumerationen när som helst.

Kontakta Affären

Skicka ett meddelande till PILA PHARMA:

Genvägar

Dela

Kategori